# HUTCHMED (China) Ltd: Form 20-F for the period ended Dec 31, 2023

- Company: [HUTCHMED (China) Ltd](/companies/hcm.md) (CIK 1648257)
- Form: 20-F
- Filed: 2024-02-28
- Accepted by EDGAR: Feb 28, 2024, 06:40 ET
- Period: 2023-12-31
- Accession: 0001104659-24-028454
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1648257/000110465924028454/hcm-20231231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1648257/000110465924028454/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2023-01-01 to 2023-12-31 | $838.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months, 2023-01-01 to 2023-12-31 | $302.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2023-01-01 to 2023-12-31 | $18.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2023-01-01 to 2023-12-31 | $759.0k | us-gaap:InterestExpense |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | $4.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | $100.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | $0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2023-01-01 to 2023-12-31 | 869,196,348 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | $219.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-31 | $32.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months, 2023-01-01 to 2023-12-31 | $9.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-12-31 | $283.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-12-31 | $1.10bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-31 | $1.28bn | us-gaap:Assets |
| Current liabilities | at 2023-12-31 | $403.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-12-31 | $536.4m | us-gaap:Liabilities |
| Long-term debt | at 2023-12-31 | $48.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2023-12-31 | $31.2m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2023-12-31 | $31.2m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2023-12-31 | $730.5m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2023-12-31 | 871,256,270 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1648257/000110465924028454/hcm-20231231x20f.htm

Filed Feb 28, 2024.
Source: SEC EDGAR, the filing index for accession 0001104659-24-028454. Last ingested by Listed: Nov 5, 2026, 11:21 ET. No prices; not investment advice.